New data on the efficacy of subcutaneous immunotherapies versus intravenous therapies in NSCLC underline not only the benefits for patients but also for healthcare professionals. This is shown by analyses of a phase III study with pembrolizumab sc versus iv.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Immune sensors
Dysfunctional signaling pathways in cardiomyocytes and their role in heart disease
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- Dementia
Recognize incipient progression and identify countermeasures
- Subtype-specific risks and implications for neurological care
Suicidal tendencies in dementia
- Study report: Hidradenitis suppurativa
Comparison of rifampicin monotherapy with clindamycin/rifampicin combination
- From symptom to diagnosis
Oncology – Prostate carcinoma
- Stress-hyperglycemia quotient and machine learning
Prediction of mortality after heart surgery
- Supply models in Switzerland